(UroToday.com) Members of the forkhead transcription factor (FOX) family are important mediators of embryonic development and are known to be altered in a variety of cancers. However, to date, the functional role of FOXF1 in bladder tumorigenesis and progression has not been clearly characterized. At the 2021 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, Dr. Anirban Mitra and colleagues from the MD Anderson Cancer Center reported results of their study investigating the clinical implications of differential FOXF1 expression in bladder cancer, and potential mechanisms by which its alteration can lead to tumor metastasis.